Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

PHASE3RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

February 28, 2027

Conditions
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Interventions
DRUG

Maralixibat

Maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), the study drug (maralixibat) will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of maralixibat. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (at least 16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.

OTHER

Placebo

Placebo matched to maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), study drug will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of study drug. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.

Trial Locations (35)

10016

RECRUITING

NYU Langone Health, New York

10029

NOT_YET_RECRUITING

Mount Sinai Hospital, New York

10032

RECRUITING

Morgan Stanley Children's Hospital - NewYork Presbyterian, New York

12713

NOT_YET_RECRUITING

King Faisal Specialist Hospital & Research Center, Riyadh

13005

RECRUITING

Hôpitaux Universitaires de Marseille Timone, Marseille

19104

NOT_YET_RECRUITING

Children's Hospital of Philadelphia, Philadelphia

24127

RECRUITING

Azienda Ospedaliera Papa Giovanni XXIII, Bergamo

27520

NOT_YET_RECRUITING

Science 37, Inc (Remote-homebase Telemedicine), Morrisville

37232

NOT_YET_RECRUITING

Vanderbilt University Medical Center, Nashville

45229

NOT_YET_RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

RECRUITING

Lurie Children's Hospital, Chicago

70121

RECRUITING

Ochsner Clinic Foundation, New Orleans

77030

RECRUITING

Baylor College of Medicine, Houston

84112

NOT_YET_RECRUITING

University of Utah, Salt Lake City

90027

RECRUITING

Children's Hospital Los Angeles (CHLA), Los Angeles

90127

RECRUITING

ISMETT - Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo

94304

RECRUITING

Stanford Children's Health in Palo Alto, Palo Alto

98105

NOT_YET_RECRUITING

Seattle Children's Hospital, Seattle

Unknown

RECRUITING

Hospital de Criança de Brasília (HCB), Brasília

RECRUITING

Hospital da Criança Santo Antonio, Porto Alegre

RECRUITING

Hospital Sírio-Libanês, São Paulo

RECRUITING

Hôpital Femme Mère Enfant, Lyon

RECRUITING

Hôpital Kremlin Bicêtre, Paris

NOT_YET_RECRUITING

Universitätsklinikum Hamburg Eppendorf - Klinik für Kinder- und Jugendmedizin, Hamburg

NOT_YET_RECRUITING

LMU Klinikum - Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, Munich

RECRUITING

Hotel Dieu de France, Beirut

NOT_YET_RECRUITING

Hospital Infantil de México Federico Gómez, Mexico City

NOT_YET_RECRUITING

Consultario de Joshue David Covarrubias Esquer, Zapopan

RECRUITING

Instytut Pomnik Centrum Zdrowia Dziecka, Warsaw

RECRUITING

Hospital Sant Joan de Deu, Barcelona

RECRUITING

Hospital Universitario Vall d'Hebron, Barcelona

RECRUITING

Hospital Universitario La Paz, Madrid

RECRUITING

King's College Hospital NHS Foundation Trust, London

T6G 2B7

NOT_YET_RECRUITING

Stollery Children's Hospital, Edmonton

00165

RECRUITING

Ospedale Pediatrico Bambino Gesu, Rome

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY